“The results from this preliminary study demonstrated that high dose leronlimab was significantly better at reversing liver fibrosis compared to an IgG 4 isotype control and demonstrated a trend toward better fibrosis reversal compared to Resmetirom. The final results from that study have now also demonstrated that leronlimab (both high and low dose) was significantly better than Resmetirom at reversal of fat deposition (steatosis) in the liver. These exciting findings have been submitted as a late breaker abstract to the MASH TAG conference and, if accepted, will be presented at the meeting in January.”

“As a side note, we have been contacted by colleagues at a major academic institution who indicated that, if the liver fibrosis reversal results are confirmed in the follow-up studies, they would be interested in funding a pilot study of leronlimab in the treatment of patients with pulmonary fibrosis at their own center.”


Better than resmetirom…let that sink in. That one-trick pony might be put out to pasture. The “colleagues at a major academic institution” are also extrapolating from deductive reason the implications for pulmonary fibrosis…often attended by pulmonary hypertension which can lead to right sided heart failure, it profoundly impacts life expectancy which drops to 2-5 years. Leronlimab is not just “better than”, it is a game-changer clinically and peaks the interest of clinicians for a reason.